2-O-methyl-α-D-glucose | 24436-13-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-O-methyl-α-D-glucose
• 英文别名: 2-O-methyl-alpha-D-glucopyranose；(2S,3R,4S,5S,6R)-6-(hydroxymethyl)-3-methoxyoxane-2,4,5-triol
• CAS: 24436-13-3
• 化学式: C₇H₁₄O₆
• 分子量: 194.185
• InChiKey: UMPNFVHHMOSNAC-ZFYZTMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-O-methyl-α-D-glucose 生成 2-O-methyl-β-D-glucose
  参考文献：
  名称：

  REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246

  摘要：

  DOI：
• 作为产物：
  描述：

  2-O-methyl-β-D-glucose 生成 2-O-methyl-α-D-glucose
  参考文献：
  名称：

  REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246

  摘要：

  DOI：

文献信息

• Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
  申请人：FRICK Wendelin

  公开号：US20110059910A1

  公开（公告）日：2011-03-10

  The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of type I and type II diabetes.

  这项发明涉及取代芳香族氟糖苷衍生物，以及其生理兼容盐和生理功能衍生物。该发明还涉及降低血糖和治疗I型和II型糖尿病的方法。
• Methods And Systems For Growing Plants Using Silicate-Based Substrates, Cultivation Of Enhanced Photosynthetic Productivity And Photosafening By Utilization Of Exogenous Glycopyranosides For Endogenous Glycopyranosyl-Protein Derivatives, And Formulations, Processes And Systems For The Same
  申请人：Innovation Hammer, LLC

  公开号：US20140331555A1

  公开（公告）日：2014-11-13

  Methods for promoting plant growth based on novel photosafening treatment regimes with glycopyranosides including glycopyranosylglycopyranosides, and aryl-a-D-glycopyranosides, and more specifically, with one or more compounds comprising terminal mannosyl-triose, optionally in the presence of light enhanced by one or more light reflecting and/or refracting members such as silicon-based substrates. Furthermore, chemical synthesis processes for the above compounds are disclosed for general application to plants. Silicate microbeads of the like are distributed over the ground or substrate in which roots of a plant are supported and planted, beneath and around a plant in a manner that light is refracted or reflected toward the phylloplane.

  基于新型光保护处理方案促进植物生长的方法，包括甘露聚糖苷类化合物，如甘露聚糖苷和芳基-a-D-甘露聚糖苷，更具体地，使用含有端基甘露三糖的一个或多个化合物，可选地在存在硅基基底等一个或多个反射和/或折射光的成员的情况下增强光线。此外，还公开了上述化合物的化学合成过程，以供普遍应用于植物。类似的硅酸盐微珠分布在植物的根部支撑和种植的地面或基质上，在植物的下方和周围，使光线以折射或反射的方式朝向叶面。
• Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
  申请人：Sugen. Inc.

  公开号：US20030100555A1

  公开（公告）日：2003-05-29

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。
• [EN] PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES
  申请人：GENZYME CORP

  公开号：WO2009154747A1

  公开（公告）日：2009-12-23

  This invention relates to crosslinked amine-containing polymers for binding compounds or ions, and more specifically relates to pharmaceutically acceptable compositions for binding compounds or ions that include crosslinked amine-containing polymers. The pharmaceutically acceptable composition includes, for example, crosslinked polyamine particles, or pharmaceutically acceptable salts thereof, having a particle size distribution wherein greater than 10 vol.% of the particles have a particle size greater than 500 μm.

  这项发明涉及交联胺含有聚合物用于结合化合物或离子，更具体地涉及用于结合化合物或离子的药用可接受组合物，其中包括交联胺含有聚合物。药用可接受组合物包括例如交联聚胺颗粒或其药用可接受盐，具有粒径分布，其中大于10体积%的颗粒具有大于500μm的粒径。
• SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES
  申请人：Sato Tsutomu

  公开号：US20110275703A1

  公开（公告）日：2011-11-10

  The present invention provides a compound represented by Formula (II): wherein R 1 is a chlorine atom, a fluorine atom, a methyl group or an ethynyl group; Ar is a group represented by the following Formula (a), Formula (b), Formula (c) or Formula (d): wherein R 2 is a C 1-6 alkyl group which may be substituted with one or more halogen atoms, a C 1-6 alkoxy group which may be substituted with one or more halogen atoms, a C 1-3 alkylthio group, a halogen atom, a C 1-3 alkylcarbonyl group or a C 2-5 alkynyl group which may be substituted with —OR 4 ; R 3 is a hydrogen atom or a C 1-3 alkyl group; R 4 is a hydrogen atom or a C 1-3 alkyl group; provided that Ar is a group represented by Formula (a) when R 1 is a fluorine atom, methyl group or an ethynyl group, and that R 2 is methoxy group, an ethoxy group, an isopropyl group, a propyl group, a trifluoromethyl group, a trifluoromethoxy group, 2-fluoroethyl group or 1-propynyl group when R 1 is a methyl group or a pharmaceutically acceptable salt or a solvate thereof and a pharmaceutical agent, a pharmaceutical composition and so on comprising the compound.

  本发明提供了一种由式（II）表示的化合物：其中R1是氯原子、氟原子、甲基基团或乙炔基；Ar是由以下式（a）、式（b）、式（c）或式（d）表示的基团：其中R2是可以用一个或多个卤素原子取代的C1-6烷基基团、可以用一个或多个卤素原子取代的C1-6烷氧基团、C1-3烷基硫基团、卤素原子、C1-3烷基羰基团或可以用—OR4取代的C2-5炔基团；R3是氢原子或C1-3烷基基团；R4是氢原子或C1-3烷基基团；前提是当R1是氟原子、甲基基团或乙炔基时，Ar是由式（a）表示的基团，当R1是甲基基团时，R2是甲氧基团、乙氧基团、异丙基团、丙基团、三氟甲基团、三氟甲氧基团、2-氟乙基基团或1-丙炔基团；以及包括该化合物的药学上可接受的盐或溶剂，以及包括药物代理、药物组合物等的制药剂。